Claudio Rigatto

Claudio Rigatto

Auto-generated profile, based on publicly available information

Claudio Rigatto

Department of Internal Medicine, University of Manitoba, Winnipeg, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
JHJulie Ho
Julie Ho
NTNavdeep Tangri
Navdeep Tangri
PKPaul Komenda
Paul Komenda
AKAmit Kaushal
Amit Kaushal
MSManish M Sood
Manish M Sood
CRClaudio Rigatto
Claudio Rigatto
Background Early accurate detection of acute kidney injury (AKI) occurring after cardiac surgery may improve morbidity and mortality. Although several novel biomarkers have been developed for the early detection of AKI, their clinical utility in the critical intraoperative and immediate postoperative period remains unclear. Study Design Systematic review and meta-analysis. Setting & Population Adult patients having cardiac surgery. Selection Criteria for Studies EMBASE, CINAHL, Cochrane Library, Scopus, and PubMed from January 1990 until January 2015 were systematically searched for cohort studies reporting the utility of novel biomarkers for the early diagnosis of AKI after adult cardiac surgery. Reviewers extracted data for study design, population, timing of biomarker measurement and AKI occurrence, biomarker performance (area under the receiver operating characteristic curve [AUROC]), and risk of bias. Index Tests Novel urine, plasma, and serum AKI biomarkers, measured intraoperatively and in the early postoperative period (<24 hours). Reference Tests AKI was defined according to the RIFLE, AKIN, or 2012 KDIGO criteria. Results We found 28 studies reporting intraoperative and/or early postoperative measurement of urine (n = 23 studies) or plasma or serum (n = 12 studies) biomarkers. Only 4 of these studies measured biomarkers intraoperatively. Overall, intraoperative discrimination by the urine biomarkers neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury marker 1 (KIM-1) demonstrated AUROCs < 0.70, whereas N-acetyl-β-d-glucosaminidase (NAG) and cystatin C had AUROCs < 0.75. In the immediate 24-hour postoperative period, the urine biomarkers NGAL (16 studies), KIM-1 (6 studies), and liver-type fatty acid binding protein (6 studies) exhibited composite AUROCs of 0.69 to 0.72. The composite AUROCs for postoperative urine cystatin C, NAG, and interleukin 18 were ≤0.70. Similarly, the composite AUROCs for postoperative plasma NGAL (6 studies) and cystatin-C (5 studies) were <0.70. Limitations Heterogeneous AKI definitions. Conclusions In adults, known urinary, plasma, and serum biomarkers of AKI possess modest discrimination at best when measured within 24 hours of cardiac surgery.

1 November 2017 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
ESElizabeth Simonsen
Elizabeth Simonsen
PKPaul Komenda
Paul Komenda
BLBlake Lerner
Blake Lerner
NANicole Askin
Nicole Askin
CBClara Bohm
Clara Bohm
CRClaudio Rigatto
Claudio Rigatto
Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients. The optimal treatments for uremic pruritus are not well defined. Systematic review. Adult patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. PubMed, CINAHL, Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and ClinicalTrials.gov from their inception to March 6, 2017, were systematically searched for randomized controlled trials (RCTs) of uremic pruritus treatments in patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. 2 reviewers extracted data independently. Risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. Any intervention for the treatment of uremic pruritus was included. A quantitative change in pruritus intensity on a visual analogue, verbal rating, or numerical rating scale. 44 RCTs examining 39 different treatments were included in the review. These treatments included gabapentin, pregabalin, mast cell stabilizers, phototherapy, hemodialysis modifications, and multiple other systemic and topical treatments. The largest body of evidence was found for the effectiveness of gabapentin. Due to the limited number of trials for the other treatments included, we are unable to comment on their efficacy. Risk of bias in most studies was high. Heterogeneity in design, treatments, and outcome measures rendered comparisons difficult and precluded meta-analysis. Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak. Large, simple, rigorous, multiarm RCTs of promising therapies are urgently needed.

22 October 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SWSimon R Walker
Simon R Walker
KGKamalpreet Gill
Kamalpreet Gill
KMKerry Macdonald
Kerry Macdonald
PKPaul Komenda
Paul Komenda
CRClaudio Rigatto
Claudio Rigatto
NTNavdeep Tangri
Navdeep Tangri
Background: Frailty is a condition characterized by a decline in physical function and functional capacity. Common symptoms of frailty, such as weakness and exhaustion, are prevalent in patients with chronic kidney disease (CKD). The increased vulnerability of frail patients with coexisting CKD may place them at a heightened risk of encountering additional health complications. The purpose of this systematic review was to explore the link between frailty, CKD and clinical outcomes. Methods: We searched for cross sectional and prospective studies in the general population and in the CKD population indexed in EMBASE, Pubmed, Web of Science, CINAHL, Cochrane and Ageline examining the association between frailty and CKD and those relating frailty in patients with CKD to clinical outcomes. Results: We screened 5,066 abstracts and retrieved 108 studies for full text review. We identified 7 studies associating frailty or physical function to CKD. From the 7 studies, we identified only two studies that related frailty in patients with CKD to a clinical outcome. CKD was consistently associated with increasing frailty or reduced physical function [odds ratios (OR) 1.30 to 3.12]. In patients with CKD, frailty was associated with a greater than two-fold higher risk of dialysis and/or death [OR from 2.0 to 5.88]. Conclusions: CKD is associated with a higher risk of frailty or diminished physical function. Furthermore, the presence of frailty in patients with CKD may lead to a higher risk of mortality. Further research must be conducted to understand the mechanisms of frailty in CKD and to confirm its association with clinical outcomes.

17 December 2017 in Sensors
Verified
Journal Article
Open access
PDF file
JWJiandong Wu
Jiandong Wu
MDMeili Dong
Meili Dong
SSSusy Santos
Susy Santos
CRClaudio Rigatto
Claudio Rigatto
YLYong Liu
Yong Liu
FLFrancis Lin
Francis Lin
Cardiovascular disease (CVD) and cancer are two leading causes of death worldwide. CVD and cancer share risk factors such as obesity and diabetes mellitus and have common diagnostic biomarkers such as interleukin-6 and C-reactive protein. Thus, timely and accurate diagnosis of these two correlated diseases is of high interest to both the research and healthcare communities. Most conventional methods for CVD and cancer biomarker detection such as microwell plate-based immunoassay and polymerase chain reaction often suffer from high costs, low test speeds, and complicated procedures. Recently, lab-on-a-chip (LoC)-based platforms have been increasingly developed for CVD and cancer biomarker sensing and analysis using various molecular and cell-based diagnostic biomarkers. These new platforms not only enable better sample preparation, chemical manipulation and reaction, high-throughput and portability, but also provide attractive features such as label-free detection and improved sensitivity due to the integration of various novel detection techniques. These features effectively improve the diagnostic test speed and simplify the detection procedure. In addition, microfluidic cell assays and organ-on-chip models offer new potential approaches for CVD and cancer diagnosis. Here we provide a mini-review focusing on recent development of LoC-based methods for CVD and cancer diagnostic biomarker measurements, and our perspectives of the challenges, opportunities and future directions.

1 November 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
BSBradford Strijack
Bradford Strijack
JMJulie Mojica
Julie Mojica
MSManish M Sood
Manish M Sood
PKPaul Komenda
Paul Komenda
JBJoe Bueti
Joe Bueti
CRClaudio Rigatto
Claudio Rigatto
Admission rates and outcomes of patients who have ESRD and are admitted to an intensive care unit (ICU) are not well defined. We conducted a historical cohort study using a prospective regional ICU database that captured all 11 adult ICUs in Winnipeg, Canada. Between 2000 and 2006, there were 34,965 total admissions to the ICU, 1173 (3.4%) of which were patients with ESRD. The main admission diagnoses among patients with ESRD were cardiac disease (31%), sepsis (15%), and arrest (10%). Compared with other patients in the ICU, those with ESRD were significantly younger but had more diabetes, peripheral arterial disease, and higher APACHE II (Acute Physiology and Chronic Health Evaluation II) scores; mean length of stay in the ICU was similar, however, between these two groups. Restricting the analysis to first admissions to the ICU, unadjusted in-hospital mortality was higher for patients with ESRD (16 versus 11%; P < 0.0001), but this difference did not persist after adjustment for baseline illness severity. In conclusion, although ESRD associates with increased mortality among patients who are admitted to the ICU, this effect is mostly a result of comorbidity.

1 January 2015 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
SWSimon R. Walker
Simon R. Walker
RBRanveer Brar
Ranveer Brar
FEFrederick Eng
Frederick Eng
PKPaul Komenda
Paul Komenda
CRClaudio Rigatto
Claudio Rigatto
NTNavdeep Tangri
Navdeep Tangri
Background: Frailty, a manifestation of unsuccessful aging, is highly prevalent in people with chronic kidney disease (CKD) and is associated with comorbid conditions in cross-sectional studies. Longitudinal studies investigating the progression of frailty in those with advanced non-dialysis CKD are lacking. Objectives: Canadian Frailty Observation and Interventions Trial (CanFIT). To determine the natural history, prevalence of perceived and measured frailty and its association with dialysis treatment choices and adverse outcomes in patients with advanced CKD. Design: Longitudinal observational study, designed to collect data from 600 participants over 2 years. Setting: Interprofessional non-dialysis CKD clinics at four tertiary health care centres in central Canada. Patients: People with CKD stage 4 and 5 (eGFR <30 ml/min/1.73 m2) who are not on dialysis at enrollment. Measurements: Multiple Frailty Definitions: Short Physical Performance Battery (SPPB), Fried Frailty Criteria, Frailty Index. Dialysis start: In-Centre Hemodialysis, Home Hemodialysis or Peritoneal Dialysis Outcomes: Death, Opt-out or Lost to follow up. Methods: We will perform physical and cognitive assessments annually. We plan to analyze the relationships between frailty, treatment choices and patient centered outcomes. Results: We have recruited 217 participants in 2 centres; of these, 56 % had reduced physical function at baseline, as defined by the SPPB. Risk of reduced physical function was 8 fold higher in those with diabetes after adjusting for age, gender, eGFR and comorbidities. Limitations: Referred population, use of SPPB as a measure of frailty, inter-operator variability in measurement of hand grip and gait speed, cross-sectional analysis of baseline data in the subset recruited to date. Conclusions: People with advanced CKD have a high burden of reduced physical function, especially those with diabetes. We will continue enrollment into the CanFIT study to further understand the clinical history of CKD and frailty in this population.